MétaCan
Menu
Back to cohort
Record W3010489206

A pharmaceutical approach to achieve synergy in vivo: A fixed ratio formulation of Irinotecan and Floxuridine for treatment of colorectal cancer

2004· article· en· W3010489206 on OpenAlexaff
Lawrence D. Mayer, Troy O. Harasym, Natashia Harasym, Paul Tardi, Yu Shu, Cecelia Suragh, Eva-Maria Simms, Marcel B. Bally

Bibliographic record

VenueCancer Research · 2004
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer therapeutics and mechanisms
Canadian institutionsCelator Pharmaceuticals (Canada)
Fundersnot available
KeywordsIrinotecanFloxuridineIn vivoPharmacologyColorectal cancerDrugChemistryCancerMedicineInternal medicineFluorouracilBiology
DOInot available

Abstract

fetched live from OpenAlex

550 Purpose: To define a fixed ratio formulation of irinotecan and floxuridine (CPX-1) for use in the treatment of colorectal cancer. Methods: The cytotoxic effects of irinotecan and floxuridine were examined alone and combined at various fixed ratios in a number of tumor cell lines. These in vitro data were analyzed utilizing the median effect principle (Chou and Talalay, Adv Enzyme Regul, 22: 27-55, 1984). Liposomal formulations were developed for the drug combination with the goal of identifying a single lipid composition capable of encapsulating both drugs in a manner where the rate of drug release from the liposomes following intravenous administration was matched for both agents. The resulting co-encapsulated fixed ratio CPX-1 formulation was then assessed in a number of in vivo tumor models. Results: In vitro results demonstrate that synergistic interactions for irinotecan and floxuridine combinations were dependent on drug-to-drug ratio. In the human colorectal cell lines HCT-116 and HT-29, mole ratios of irinotecan and floxuridine of 1:1, 1:5 and 1:10 produced the largest synergistic effects over the broadest range of effective doses. Exposure of cancer cells to a mole ratio of 10:1 typically resulted in additive or antagonistic interactions. A mole ratio of 1:1 was defined as optimal for a range of tumor cell lines and a liposomal formulation was developed with co-encapsulated irinotecan and floxuridine at this ratio. Evaluations of the co-encapsulated drugs indicated that following i.v. administration the concentrations of each drug in the plasma were comparable over time, thus the drug-to-drug ratio in the plasma was maintained at the optimal 1:1 mole ratio. For HT-29 efficacy studies, delays in tumor growth achieved following treatment with the maximum tolerated dose of the free drug cocktail were significantly less than those achieved with the fixed ratio formulation administered at an 8-fold lower dose. Control tumors grew to 500 mg 28 days after cell inoculation. Using identical drug doses (25 mg/kg of irinotecan and 9.25 mg/kg floxuridine) and treatment schedule (Q7D x 3), HT29 tumors grew to 500 mg by day 30 and 60 following treatment with free irinotecan:floxuridine and CPX-1, respectively. Similar results were seen when evaluating therapy in the HCT-116 xenograft tumor model. Conclusion: Irinotecan and floxuridine acted synergistically in vitro when combined at a molar ratio of 1:1. When evaluated in preclinical models of human solid tumors, a fixed ratio formulation exhibited dramatic improvements in antitumor activity.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.008
Threshold uncertainty score0.334

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.080
GPT teacher head0.415
Teacher spread0.334 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2004
Admission routes1
Has abstractyes

Explore more

Same venueCancer ResearchSame topicCancer therapeutics and mechanismsFrench-language works237,207